MedTrace Logo

SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma

NCT00503867 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-12-10

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to determine the safety and toxicity of treatment with SIR-Spheres® in patients with unresectable primary liver cancer or hepatocellular carcinoma (HCC). Other purposes of this study include assessment of the effect of treatment on overall survival, the length of time it takes for the disease to worsen, if and how the treatment affects the patient's quality of life, and if and how the cancer responds to the treatment.

Conditions

  • Carcinoma, Hepatocellular
  • Hepatoma

Interventions

DEVICE

SIR-Spheres microspheres

SIR-Spheres Yttrium-90 microspheres

Sponsors & Collaborators

  • Sirtex Medical

    lead INDUSTRY

Principal Investigators

  • Ravi Murthy, MD · M.D. Anderson Cancer Center

  • T. Clark Gamblin, MD · UPMC Liver Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-18
Primary Completion
2010-03-09
Completion
2010-03-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00503867 on ClinicalTrials.gov